Search This Blog

Thursday, June 1, 2023

Elon Musk Encouraged By Government To Expand Business, Investment In Shanghai

 Tesla's relationship with China continues to look cozy heading into the second half of 2023, with Shanghai party chief Chen Jining reportedly encouraging Elon Musk to expand his business in China.

At the conclusion of a trip through China for Musk, on Thursday Bloomberg reported in a wrap-up that Musk was told to expand his investment and businesses in Shanghai, citing an official government statement. 

The city is reportedly seeking "deepening cooperation with Tesla on electric vehicles and energy storage sector". Tesla "hopes to keep deepening cooperation" with the city, Bloomberg noted. 

Recall, we wrote days ago how Musk was visiting China for the first time in three years. We reported yesterday that Musk told Chinese Foreign Minister Qin Gang in Beijing that Tesla opposes "decoupling" and is willing to invest more in China.

Dan Ives, an analyst at Wedbush, shared his thoughts on Musk's first visit to China in three years yesterday. He said the visit comes amid a worsening EV price war and stressed the importance for Tesla to capture a greater market share in China versus domestic competitors. 

 "Playing nice in the sandbox in Beijing is something the Street is laser-focused on to make sure there are no disruptions to Tesla's expansion," Ives wrote in the note. 

Elon Musk's tour of the country started earlier this week, on Tuesday. As we noted then, Tesla's second-biggest market, after the US, is China, where the company operates a massive factory in Shanghai. The world's second richest person met top Chinese officials and visited Tesla's Shanghai factory. 

CCP's mouthpiece Global Times tweeted earlier this month, "Shanghai will further deepen cooperation with Tesla, pushing its layout on autonomous driving, robots and other business sectors in the city." 

Despite souring relations between China and the US, Musk appears to be betting big on Shanghai production while other companies are rejiggering supply chains out of the world's second-largest economy to other friendlier countries. 

https://www.zerohedge.com/markets/elon-musk-encouraged-government-expand-business-investment-shanghai

Medicare to cover new Alzheimer's drug after full approval

 The Centers for Medicare & Medicaid Services said on Thursday that the U.S. Medicare health plan would cover new Alzheimer's drugs such as Eisai Co Ltd and Biogen Inc's Leqembi if they gain full U.S. approval.

Currently, Medicare - the government health plan for Americans 65 and over - will only pay for Alzheimer's disease drugs approved under the FDA's rigorous accelerated review if patients are enrolled in a clinical trial. 

https://finance.yahoo.com/news/medicare-cover-alzheimers-drug-full-130704773.html

Apple Savings Account Customers: Hard to Get Their Money Out of Goldman Sachs

Some customers said it has taken weeks to withdraw their money, and that the bank’s instructions have differed

 

Apple’s AAPL 1.32%increase; green up pointing triangle savings account, a partnership with Goldman Sachs GS -2.13%decrease; red down pointing triangle, launched in April to great fanfare. Some customers say it has been hard to get their money out. 

https://www.wsj.com/articles/apple-savings-account-customers-say-its-hard-to-get-their-money-out-of-goldman-sachs-bd8b9ccb

US debt-ceiling deal dooms Biden's revolutionary tax plans

 U.S. President Joe Biden's 2020 campaign promise to make wealthy Americans and corporations pay more in taxes to finance a range of social priorities breathed its last gasp, at least for this presidential term, with the debt ceiling deal he struck with Republicans on Saturday.

The deal to cap discretionary spending and suspend the debt ceiling contains no tax rate changes to raise revenue; it also slashes new funding Biden had allocated to the hollowed-out Internal Revenue Service. The agreement caps Republicans' successful defense of the debt-boosting 2017 Trump tax cuts against withering criticism from Biden and several attempts by his Democrats to reverse them for wealthy Americans.

Barring an unlikely Democratic sweep of the White House and both chambers of Congress in 2024, major changes to the U.S. tax code are now seen as largely off the table until the end of 2025, when the 2017 individual tax cuts expire. Then, tax experts predict lawmakers will be forced to agree on a major tax revamp.

"Things are getting set up for a big fiscal cliff in 2025. That's the next opportunity for major changes," said William McBride, vice president of federal tax policy for the Tax Foundation, a conservative think tank in Washington.

Polls show the idea of fighting glaring income inequality with tax increases on the wealthy and corporations is hugely popular with Democratic and Republican voters.

TAX CHANGES ARE TOUGH

Biden's unrealized campaign tax pledges illustrate the political difficulty of changing the U.S. tax code, barring a commanding majority in Congress.

His $4 trillion, two-part "Build Back Better" plan included infrastructure, clean energy incentives, workforce development, child care, paid family leave, free community college, expanded child tax credits and other initiatives.

He proposed over $3.5 trillion in new taxes, including raising the corporate rate to 28% from 21% and returning the top individual rate to 39.6% from 37% and taxing capital gains at those rates for Americans earning over $1 million. He promised no increases for those earning under $400,000 a year.

But opposition from Republicans and Democratic senators Joe Manchin and Kyrsten Sinema, now an Independent, forced Biden to scale back his revenue plans. He did manage to win new cryptocurrency tax reporting rules in the infrastructure bill and a new 15% corporate alternative minimum tax in the climate-focused Inflation Reduction Act, to achieve $238 billion in deficit cuts over 10 years.

Biden presented his tax hikes and social agenda one last time, largely for campaign purposes, in his fiscal 2024 budget request in March, proposing to raise $5.5 trillion in new revenue and cutting deficits by $3 trillion over a decade.

But in the debt-ceiling negotiations, the president did not insist on tax revenue-raisers, and sacrificed part of his revenue crown jewel - $80 billion in new funding over a decade to modernize the IRS to beef up enforcement against tax cheats. The IRS will cede $20 billion over two years to other spending priorities.

"House Republicans have successfully blocked every penny of President Biden’s tax hikes on families, farmers, and small businesses in the debt ceiling deal and protected the 2017 Tax Cuts and Jobs Act from repeal," said U.S. House Ways and Means Chairman Jason Smith.

The Missouri Republican added that Americans want Congress to build on the Trump tax cuts "with more tax relief."

2024 CAMPAIGN ISSUE

The 2024 presidential election is already becoming a new battle ground over taxes as both parties posture over the expiration of 2017 individual tax cuts and the overall level of taxation in the economy.

U.S. taxes are low compared with other wealthy countries, ranking 32nd out of 38 Organisation for Economic Co-operation and Development countries as a percentage of GDP, with a 2021 ratio of 26.8% - well below the group's 34.1% average.

White House spokesperson Michael Kikukawa said Biden would continue pushing Congress to make the "super-wealthy and biggest corporations" pay their fair share in taxes.

"This agenda is overwhelmingly popular with bipartisan majorities of the American people, and would reduce the deficit by trillions of dollars without raising taxes a penny on those making less than $400,000," Kikukawa said.

Republicans will argue for making the 2017 individual tax cuts permanent, said John Gimigliano, KPMG's head of federal tax legislative and regulatory services.

The Congressional Budget Office estimates this would add $2.8 trillion to its baseline deficit forecast just through 2033 compared with letting them expire under current law.

Democrats will advocate "a return to Build Back Better and see a push on the corporate rate, on the capital gains rate and individual rates and all the things they had hoped to do," Gimigliano said.

Steve Rosenthal, a senior fellow at the left-leaning Urban-Brookings Tax Policy Center in Washington, said it may be difficult for Biden to reprise his "very powerful" 2020 tax agenda.

"Very little of it was accomplished in the Inflation Reduction Act, and nothing was advanced as part of these debt ceiling negotiations," Rosenthal said. "So how credible will Biden be running on a platform of closing loopholes and raising taxes on the rich and corporations?"

https://finance.yahoo.com/news/analysis-us-debt-ceiling-deal-101548585.html

Bayer inks Cedilla cancer deal, betting take on tough target will beat Pfizer

 Bayer is joining Blueprint Medicines, Incyte and Pfizer in the race to develop a selective CDK2 inhibitor, paying Cedilla Therapeutics an undisclosed sum for a preclinical challenger to the more advanced rivals.

Evidence that CDK2 is involved in processes that drive forms of breast, ovarian, uterine, stomach and esophageal cancers has spurred decades of research. Interest in the target intensified as it became clear that the kinase is implicated in changes that create breast cancers that are resistant to CDK4/6 inhibitors such as Pfizer’s Ibrance, Novartis’ Kisqali and Eli Lilly’s Verzenio.

CDK2 is a tough target, though, because researchers need to create molecules with selectivity against its isoforms to avoid an intolerable toxicity profile. Cedilla emerged as a biotech with a plan for how to beat the toxicity problem in 2021, when it disclosed its CDK2 program and raised $82.6 million.

Investors including RA Capital Management and Third Rock Ventures bet on Cedilla in the belief that its conditional inhibitors are a good fit for targets including CDK2. The inhibitors only modulate their targets when they are in a certain condition. 

In the case of CDK2, the condition is binding to Cyclin E. Focusing on the Cyclin E1/CDK2 complex enabled Cedilla to identify a previously unreported binding site. If the biotech is right, targeting the binding site will improve on the selectivity of other CDK2 inhibitors and result in a more favorable risk-benefit profile. 

Bayer has bought into the idea. In return for a financial package featuring upfront, milestone and royalty payments, the size of which remains under wraps, the German drugmaker has secured full rights to work on Cedilla’s Cyclin E1/CDK2 complex inhibitors. The Cedilla pipeline lists the program between preclinical and IND. 

The upshot is Bayer has ceded a head start to its rivals for the CDK2 market. Pfizer is set to present phase 1/2a data on its candidate, PF-07104091, this week. Incyte and Blueprint Medicines joined Pfizer in the clinic last year, kicking off early-phase trials of INCB123667 and BLU-222, respectively. Blueprint was held up by a clinical hold but quickly fixed the problem and began working to resume enrollment in March.

https://www.fiercebiotech.com/biotech/bayer-inks-cedilla-cancer-deal-betting-take-tough-target-will-beat-pfizer-and-chasing-pack

Pfizer says its experimental antibiotic combo can treat some superbug infections

 Pfizer Inc said on Thursday that data from its late-stage trials showed its experimental combination of antibiotics was effective in treating some infections caused by drug-resistant bacteria.

The late-stage studies compared the experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) with a combination of two other antibiotics - meropenem and colistin - for the treatment of complicated intra-abdominal infections and types of hospital-acquired pneumonia.

Pfizer said the data from the studies shows the antibiotic combination of aztreonam-avibactam is effective and well-tolerated in treating infections caused by gram-negative bacteria.

Hospital-acquired pneumonia occurs in patients at least two-three days after being admitted, or in those who have life-threatening lung infections with high mortality rates, and who are on mechanical breathing machines. 

https://finance.yahoo.com/news/1-pfizer-says-experimental-antibiotic-142848070.html

Rockwell Med financials, outlook

 

  • Achieved fourth consecutive quarter of revenue growth with new high of $19.7 million, representing a 22.4% increase over the same period in 2022

  • Achieved $2.6 million in gross profit, representing a 425% increase over the same period in 2022

  • Continued to reduce expenses and improve earnings per share with focus on driving enhanced business performance

  • Entered into several new long-term supply, product purchase, and distribution agreements

  • Reiterates 2023 guidance of revenue between $78.0 million and $82.0 million and gross profit between $7.0 million and $9.0 million